After expanding a drug trial to test a pain treatment gel, Raleigh drug developer BioDelivery Sciences International reached a milestone in testing that gel it plans to market as a pain medication. Earlier this year, preliminary test results on the gel, called Clonodine Topical Gel, weren't giving BioDelivery what it hoped for, so it upped the enrollment projections from 140 patients to 220 patients.